A detailed history of John G Ullman & Associates Inc transactions in Pfizer Inc stock. As of the latest transaction made, John G Ullman & Associates Inc holds 337,323 shares of PFE stock, worth $8.89 Million. This represents 1.51% of its overall portfolio holdings.

Number of Shares
337,323
Previous 343,265 1.73%
Holding current value
$8.89 Million
Previous $9.6 Million 1.65%
% of portfolio
1.51%
Previous 1.52%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$27.7 - $31.39 $164,593 - $186,519
-5,942 Reduced 1.73%
337,323 $9.76 Million
Q2 2024

Aug 08, 2024

SELL
$25.26 - $29.6 $237,595 - $278,417
-9,406 Reduced 2.67%
343,265 $9.6 Million
Q1 2024

May 06, 2024

SELL
$25.89 - $29.73 $1.42 Million - $1.64 Million
-55,037 Reduced 13.5%
352,671 $9.79 Million
Q4 2023

Jan 31, 2024

SELL
$26.13 - $33.94 $4.42 Million - $5.74 Million
-169,128 Reduced 29.32%
407,708 $11.7 Million
Q3 2023

Nov 01, 2023

SELL
$32.09 - $37.51 $580,668 - $678,743
-18,095 Reduced 3.04%
576,836 $19.1 Million
Q2 2023

Aug 21, 2023

BUY
$36.12 - $41.79 $87,049 - $100,713
2,410 Added 0.41%
594,931 $21.8 Million
Q1 2023

May 05, 2023

SELL
$39.39 - $51.28 $589,628 - $767,610
-14,969 Reduced 2.46%
592,521 $24.2 Million
Q4 2022

Feb 08, 2023

SELL
$41.75 - $54.5 $361,137 - $471,425
-8,650 Reduced 1.4%
607,490 $31.1 Million
Q3 2022

Oct 19, 2022

SELL
$43.76 - $53.42 $284,440 - $347,230
-6,500 Reduced 1.04%
616,140 $27 Million
Q2 2022

Jul 27, 2022

SELL
$46.53 - $55.17 $158,248 - $187,633
-3,401 Reduced 0.54%
622,640 $32.6 Million
Q1 2022

Apr 29, 2022

SELL
$45.75 - $56.69 $417,514 - $517,352
-9,126 Reduced 1.44%
626,041 $32.4 Million
Q4 2021

Jan 26, 2022

SELL
$41.32 - $61.25 $342,253 - $507,333
-8,283 Reduced 1.29%
635,167 $37.5 Million
Q3 2021

Nov 02, 2021

SELL
$39.25 - $50.42 $398,897 - $512,418
-10,163 Reduced 1.55%
643,450 $27.7 Million
Q2 2021

Jul 23, 2021

BUY
$35.91 - $40.68 $175,456 - $198,762
4,886 Added 0.75%
653,613 $25.6 Million
Q1 2021

Apr 22, 2021

BUY
$33.49 - $37.77 $1.39 Million - $1.56 Million
41,416 Added 6.82%
648,727 $23.5 Million
Q4 2020

Feb 05, 2021

BUY
$33.47 - $42.56 $1.94 Million - $2.47 Million
57,985 Added 10.56%
607,311 $22.4 Million
Q3 2020

Nov 06, 2020

BUY
$31.75 - $37.25 $348,202 - $408,520
10,967 Added 2.04%
549,326 $20.2 Million
Q2 2020

Jul 29, 2020

BUY
$30.12 - $36.54 $53,944 - $65,443
1,791 Added 0.33%
538,359 $17.6 Million
Q1 2020

Apr 14, 2020

BUY
$27.03 - $38.62 $1.31 Million - $1.88 Million
48,601 Added 9.96%
536,568 $17.5 Million
Q4 2019

Jan 29, 2020

BUY
$32.92 - $37.36 $908,394 - $1.03 Million
27,594 Added 5.99%
487,967 $19.1 Million
Q3 2019

Oct 21, 2019

BUY
$32.49 - $42.13 $798,116 - $1.03 Million
24,565 Added 5.64%
460,373 $16.5 Million
Q2 2019

Aug 02, 2019

SELL
$36.98 - $41.52 $113,528 - $127,466
-3,070 Reduced 0.7%
435,808 $18.9 Million
Q1 2019

Apr 30, 2019

SELL
$37.5 - $41.2 $217,275 - $238,712
-5,794 Reduced 1.3%
438,878 $18.6 Million
Q4 2018

Jan 29, 2019

SELL
$38.47 - $43.86 $160,535 - $183,027
-4,173 Reduced 0.93%
444,672 $19.4 Million
Q3 2018

Nov 02, 2018

BUY
$34.47 - $41.81 $5,653 - $6,856
164 Added 0.04%
448,845 $19.8 Million
Q2 2018

Jul 23, 2018

SELL
$32.98 - $35.16 $236,169 - $251,780
-7,161 Reduced 1.57%
448,681 $16.3 Million
Q1 2018

Apr 19, 2018

BUY
$31.91 - $37.02 $74,669 - $86,626
2,340 Added 0.52%
455,842 $16.2 Million
Q4 2017

Jan 31, 2018

SELL
$33.26 - $35.29 $242,365 - $257,158
-7,287 Reduced 1.58%
453,502 $16.4 Million
Q3 2017

Nov 03, 2017

BUY
$31.0 - $34.15 $14.3 Million - $15.7 Million
460,789
460,789 $16.5 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $148B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track John G Ullman & Associates Inc Portfolio

Follow John G Ullman & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of John G Ullman & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on John G Ullman & Associates Inc with notifications on news.